Avalo Therapeutics
AVTX
6 hedge funds and large institutions have $14.2M invested in Avalo Therapeutics in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
498% more capital invested
Capital invested by funds: $2.37M → $14.2M (+$11.8M)
0.01% more ownership
Funds ownership: 0.01% → 0.02% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
33% less funds holding
Funds holding: 9 → 6 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$9.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$14K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$10K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $13.6M | +$9.38M | +4,381 | +373% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $506K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $48K | -$2.14K | -1 | -5% |
|
4
Commonwealth Equity Services
Waltham,
Massachusetts
| $11K | – | – | – |
|
5
BlackRock
New York
| $3K | – | – | – |
|
|
TWA
6
TCI Wealth Advisors
Tucson,
Arizona
| $3K | – | – | – |
|
|
7
Bank of New York Mellon
New York
| – | -$14K | -9 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$10K | -6 | Closed |
|
AVTX Hedge Fund Activity: Q3 2017 in Review
6 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2017, worth a combined $14.2M — up 498% from $2.37M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of AVTX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, adding an estimated $9.38M. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $14K sold.
- 6 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2017, down from 9 in Q2 2017.
- Funds reported $14.2M of Avalo Therapeutics stock for Q3 2017, up 498% quarter-over-quarter.
- 0 funds opened new Avalo Therapeutics positions in Q3 2017 and 2 closed out, a net change of -2 holders.
- The largest Avalo Therapeutics buyer in Q3 2017 was Armistice Capital, an estimated $9.38M added.
- The largest Avalo Therapeutics seller in Q3 2017 was Bank of New York Mellon, an estimated $14K sold.
Based on aggregated 13F filings for Q3 2017.